Serum peroxiredoxin3 is a useful biomarker for early diagnosis and assessemnt of prognosis of hepatocellular carcinoma in Chinese patients

Asian Pacific Journal of Cancer Prevention

Volumn 15, Issue 7, 2014, Pages 2979-2986

  Shi, Liang ^a   Wu, Li Li ^b   Yang, Jian Rong ^a   Chen, Xiao Fei ^a   Zhang, Yi ^a   Chen, Zeng Qiang ^a   Liu, Cun Li ^a   Chi, Sheng Ying ^a   Zheng, Jia Ying ^a   Huang, Hai Xia ^a   Yu, Fu Jun ^a   Lin, Xiang Yang ^a  

^a THE FIRST AFFILIATED HOSPITAL OF WENZHOU MEDICAL UNIVERSITY   (China)

^b WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Alpha fetoprotein; Biomarker; Hepatocellular carcinoma; Peroxiredoxin3

Indexed keywords

ALPHA FETOPROTEIN; PEROXIREDOXIN 3; PRDX3 PROTEIN, HUMAN; TUMOR MARKER;

BLOOD; CANCER STAGING; CARCINOMA, HEPATOCELLULAR; CHINA; COMORBIDITY; DISEASE COURSE; EARLY DIAGNOSIS; FEMALE; HUMAN; KAPLAN MEIER METHOD; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; METABOLISM; MIDDLE AGED; MORTALITY; PROGNOSIS; RETROSPECTIVE STUDY;

ALPHA-FETOPROTEINS; CARCINOMA, HEPATOCELLULAR; CHINA; COMORBIDITY; DISEASE PROGRESSION; EARLY DETECTION OF CANCER; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PEROXIREDOXIN III; PROGNOSIS; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 84900837526     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2014.15.7.2979     Document Type: Article

References (30)

1. Altekruse SF, McGlynn KA, Reichman ME (2009). Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol, 27, 1485-91.
2. Basu A, Banerjee H, Rojas H, et al (2011). Differential expression of peroxiredoxins in prostate cancer: consistent upregulation of PRDX3 and PRDX4. Prostate, 71, 755-65.
3. Breuhahn K, Gores G, Schirmacher P (2011). Strategies for hepatocellular carcinoma therapy and diagnostics: lessons learned from high throughput and profiling approaches. Hepatology, 53, 2112-21.
4. Dai Z, Yin J, He H, et al (2010). Mitochondrial comparative proteomics of human ovarian cancer cells and their platinumresistant sublines. Proteomics, 10, 3789-99.
5. Dietz KJ, Horling F, Konig J, Baier M (2002). The function of oroplast 2-cysteine peroxiredoxin in peroxide detoxification and its regulation. J Exp Bot, 53, 1321-29.
6. Fu J, Qiu H, Cai M, et al (2013). Low cyclin F expression in hepatocellular carcinoma associates with poor differentiation and unfavorable prognosis. Cancer Sci, 104, 508-15.
7. Huang HC, Zheng S, VanBuren V, Zhao Z (2009). Discovering disease-specific biomarker genes for cancer diagnosis and prognosis. Technol Cancer Res Treat, 9, 219-30.
8. Huh JY, Kim Y, Jeong J, et al (2012). Peroxiredoxin 3 is a key molecule regulating adipocyte oxidative stress, mitochondrial biogenesis, and adipokine expression. Antioxid Redox Signal, 16, 229-43.
9. Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90.
10. Ji D, Lu ZT, Li YQ, et al (2014) MACC1 expression correlates with pfkfb2 and survival in hepatocellular carcinoma. Asian Pac J Cancer Prev, 15, 999-1000
11. Jo M, Nishikawa T, Nakajima T, et al (2011). Oxidative stress is closely associated with tumor angiogenesis of hepatocellular carcinoma. J Gastroentero, 46, 809-21.
12. Kim K, Yu M, Han S, et al (2009). Expression of human peroxiredoxin isoforms in response to cervical carcinogenesis. Oncol Rep, 21, 1391-96.
13. Kudo M. (2010) Management of hepatocellular carcinoma: from prevention to molecular targeted therapy. Oncology, 78, 1-6.
14. Li XQ, Zhang SL, Cai Z, et al (2009). Proteomic identification of tumor-associated protein in ovarian serous cystadenocarinoma. Cancer Lett, 275, 109-16.
15. Liu L, Zhang CZ, Cai M, et al (2012). Downregulation of pololike kinase 4 in hepatocellular carcinoma associates with poor prognosis. PLoS One, 7, 41293.
16. Liu X, Feng R, Du L (2010). The role of enoyl-CoA hydratase short chain 1 and peroxiredoxin 3 in PP2-induced apoptosis in human breast cancer MCF-7 cells. FEBS Lett, 584, 3185-92.
17. Mao Y, Yang H, Xu H, et al (2010). Golgi protein 73 (GOLPH2) is a valuable serum marker for hepatocellular carcinoma. Gut, 59, 1687-93.
18. Marquardt JU, Galle PR, Teufel A (2012). [Hepatocellular carcinoma: molecular pathogenesis and novel targets for therapy]. Dtsch Med Wochenschr, 137, 855-60.
19. Marra M, Sordelli IM, Lombardi A, et al (2011). Molecular targets and oxidative stress biomarkers in hepatocellular carcinoma: an overview. J Transl Med, 9, 171.
20. Nagasue N (1998). Liver resection for hepatocellular carcinoma: indications, techniques, complications, and prognostic factors. J Hepatobiliary Pancreat Surg, 5, 7-13.
21. Pateron D, Ganne N, Trinchet JC, et al (1994). Prospective study of screening for hepatocellular carcinoma in Caucasian patients with cirrhosis. J Hepatol, 20, 65-71.
22. Qiao B, Wang J, Xie J, et al (2012). Detection and identification of peroxiredoxin 3 as a biomarker in hepatocellular carcinomaby a proteomic approach. Int J Mol Med, 29, 832-40.
23. Rabilloud T, Heller M, Gasnier F, et al (2002). Proteomics analysis of cellular response to oxidative stress. Evidence for in vivo overoxidation of peroxiredoxins at their active site. J Biol Chem, 277, 19396-401.
24. ShariffMI, Cox IJ, Gomaa AI, et al (2009). Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis and therapeutics. Expert Rev Gastroenterol Hepatol, 3, 353-67.
25. Shen Q, Fan J, Yang XR, et al (2012). Serum DKK1 as a protein biomarker for the diagnosis of hepatocellular carcinoma: a large-scale, multicentre study. Lancet Oncol, 13, 817-26.
26. Song IS, Kim HK, Jeong SH, et al (2011). Mitochondrial peroxiredoxin III is a potential target for cancer therapy. Int J Mol Sci, 12, 7163-85
27. Trachootham D, Alexandre J, Huang P. (2009). Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nat Rev Drug Discov, 8, 579-91.
28. Wonsey DR, Zeller KI, Dang CV (2002). The c-Myc target gene PRDX3 is required for mitochondrial homeostasis and neoplastic transformation. Proc Natl Acad Sci USA, 99, 6649-54.
29. Wu XY, Fu ZX, Wang XH (2010). Peroxiredoxins in colorectal neoplasms. Histol Histopathol, 25, 1297-303.
30. Yamamoto K, Imamura H, Matsuyama Y, et al (2010). AFP, AFP-L3, DCP, and GP73 as markers for monitoring treatment response and recurrence and as surrogate markers of clinicopathological variables of HCC. J Gastroenterol, 45, 1272-82.